Biogen Idec And Swedish Orphan Biovitrum Present Data On Long-Lasting Hemophilia B Therapy At The World Federation Of Hemophilia Congress
Source: Medical News Today
Saturday 31st July, 2010
0 posts Biogen Idec (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (STO: SOBI) announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-... ...
Read the full story at
Medical News Today
Email this story to a friend
Have your say on this story
